Florida Health Daily
SEE OTHER BRANDS

Your best source on healthcare and wellness news from Florida

Florida Health Daily: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.

Press releases published on April 15, 2025

Serina Therapeutics to Present at the 4th LNP Formulation & Process Development Summit

Serina Therapeutics to Present at the 4th LNP Formulation & Process Development Summit

HUNTSVILLE, AL, April 15, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, announced that Randall Moreadith, M. …

Native Path Native Hydrate Reviews [Urgent Update]: Don’t Buy Until You Read This

Native Path Native Hydrate Reviews [Urgent Update]: Don’t Buy Until You Read This

Native Hydrate by Native Path Reviews Woodhaven, N.Y., April 15, 2025 (GLOBE NEWSWIRE) -- What if the key to better hydration and muscle recovery wasn’t in sugary sports drinks but in a clean, science-backed formula? Native Hydrate by Native Path is …

Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2025

Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2025

Company Announcement Net sales of DARZALEX® in the first quarter of 2025 totaled USD 3,237 million Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, Denmark; April 15, 2025 – …

Verona Pharma to Report First Quarter 2025 Financial Results and Provide Corporate Update

Verona Pharma to Report First Quarter 2025 Financial Results and Provide Corporate Update

LONDON and RALEIGH, N.C., April 15, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the first quarter ended March 31, 2025 on Tuesday, April 29, 2025 and …

Medāna Enters the Spanish Market with an AI Platform to Transform Healthcare Across Europe

Medāna Enters the Spanish Market with an AI Platform to Transform Healthcare Across Europe

LISBON, Portugal, April 15, 2025 (GLOBE NEWSWIRE) -- Spain is about to welcome one of the most disruptive technologies in digital health. Medāna (www.medana.ai), the global startup founded by Dr. Tal Patalon , has announced its strategic entry into the …

MEDĀNA ENTRA EN EL MERCADO ESPAÑOL CON UNA PLATAFORMA DE IA PARA TRANSFORMAR LA SANIDAD EN TODA EUROPA

MEDĀNA ENTRA EN EL MERCADO ESPAÑOL CON UNA PLATAFORMA DE IA PARA TRANSFORMAR LA SANIDAD EN TODA EUROPA

LISBOA, Portugal, April 15, 2025 (GLOBE NEWSWIRE) -- España está a punto de recibir una de las tecnologías más disruptivas en salud digital. Medāna (www.medana.ai), startup internacional fundada por la Dra. Tal Patalon, ha anunciado su entrada estratégica …

Medāna Enters the Netherlands Market with an AI Platform to Transform Healthcare Across Europe

Medāna Enters the Netherlands Market with an AI Platform to Transform Healthcare Across Europe

LISBON, Portugal, April 15, 2025 (GLOBE NEWSWIRE) -- Netherlands is about to welcome one of the most disruptive technologies in digital health. Medāna (www.medana.ai), the global startup founded by Dr. Tal Patalon, has announced its strategic entry into …

MEDĀNA BETREEDT DE NEDERLANDSE MARKT MET EEN AI-PLATFORM OM DE GEZONDHEIDSZORG TE TRANSFORMEREN IN EUROPA

MEDĀNA BETREEDT DE NEDERLANDSE MARKT MET EEN AI-PLATFORM OM DE GEZONDHEIDSZORG TE TRANSFORMEREN IN EUROPA

LISSABON, Portugal, April 15, 2025 (GLOBE NEWSWIRE) -- Nederland staat op het punt een van de meest baanbrekende technologieën in de digitale gezondheidszorg te verwelkomen. Medāna (www.medana.ai), de startup opgericht door Dr. Tal Patalon, heeft zijn …

Genenta Showcases Strategic Vision at Premier Biotech Forum in Qatar

Genenta Showcases Strategic Vision at Premier Biotech Forum in Qatar

MILAN and NEW YORK, April 15, 2025 (GLOBE NEWSWIRE) -- Pierluigi Paracchi, CEO Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, will present at “Montalcini Global Biotech Tour” in Doha, Qatar on April …

HepaRegeniX completes €21.5 million financing to support clinical advancement of HRX-215 for liver regeneration

HepaRegeniX completes €21.5 million financing to support clinical advancement of HRX-215 for liver regeneration

Tuebingen, Germany, April 15, 2025 – HepaRegeniX GmbH (“HepaRegeniX”), a clinical-stage company advancing novel therapies to treat acute and chronic liver diseases, today announced the second closing and completion of a €21.5 million financing round with …

Oculis Hosts R&D Event Today to Showcase Progress on All Three Pipeline Assets

Oculis Hosts R&D Event Today to Showcase Progress on All Three Pipeline Assets

ZUG, Switzerland, April 15, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company"), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant …

Concept Life Sciences expands expertise with key appointments to Scientific Advisory Board and investments to strengthen integrated drug discovery capabilities

Concept Life Sciences expands expertise with key appointments to Scientific Advisory Board and investments to strengthen integrated drug discovery capabilities

CHAPEL-EN-LE-FRITH, United Kingdom, April 15, 2025 (GLOBE NEWSWIRE) -- Concept Life Sciences (CLS), a leading integrated drug discovery, development, and manufacturing organisation backed by Limerston Capital, today announced key strategic appointments and …

Cyprumed Enters License and Option Agreement with MSD for the Development of Oral Peptide Therapeutics

Cyprumed Enters License and Option Agreement with MSD for the Development of Oral Peptide Therapeutics

MSD obtains a Non-Exclusive License for Cyprumed’s delivery technology to develop oral peptide therapeutics Cyprumed will be eligible to receive up to $493 million in upfront, development, regulatory and sales milestones INNSBRUCK, Austria, April 15, 2025 …

1ST Biotherapeutics Joins The Michael J. Fox Foundation’s LITE Program to Advance LRRK2-Based Parkinson’s Disease Research

1ST Biotherapeutics Joins The Michael J. Fox Foundation’s LITE Program to Advance LRRK2-Based Parkinson’s Disease Research

Focus on the discovery of next-generation LRRK2 inhibitors to unlock novel biological mechanisms of action and advance new treatment options YONGIN, South Korea, April 15, 2025 – 1ST Biotherapeutics, Inc. (1STBIO), a clinical-stage biopharmaceutical …

Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases

Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases

        Partnership bolsters Boehringer’s autoimmune and inflammatory disease pipeline portfolio aiming to tackle areas of high unmet patient need.        The agreement focuses on further research and development of a novel, first-in-class bispecific …

CORXEL Receives Study May Proceed Letter from the U.S. FDA for the Phase 2 Trial of CX11 in Patients with Obesity and Overweight Conditions

CORXEL Receives Study May Proceed Letter from the U.S. FDA for the Phase 2 Trial of CX11 in Patients with Obesity and Overweight Conditions

The U.S. Phase 2 trial aims to evaluate efficacy and safety of CX11 in doses up to 200 mg and different titration schemes The trial is expected to enroll 250 patients to receive treatment over 36 weeks BERKELEY HEIGHTS, N.J., April 15, 2025 (GLOBE NEWSWIRE …

Galapagos Announces Departure of Thad Huston, CFO and COO, as of August 1, 2025

Galapagos Announces Departure of Thad Huston, CFO and COO, as of August 1, 2025

Mechelen, Belgium; April 15, 2025, 07:30 CET; regulated information – inside information – Galapagos NV (Euronext …

Galapagos kondigt het vertrek van haar CFO en COO, Thad Huston, aan per 1 augustus 2025

Galapagos kondigt het vertrek van haar CFO en COO, Thad Huston, aan per 1 augustus 2025

Mechelen, België; 15 april 2025, 07:30 CET; gereglementeerde informatie - voorwetenschap – Galapagos NV (Euronext …

Press Release: Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD

Press Release: Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD

Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD New phase 2 data for amlitelimab show efficacy in heterogeneous inflammatory asthma Lunsekimig now targeting chronic rhinosinusitis and COPD in …

Communiqué de presse : Le portefeuille de traitements contre les maladies respiratoires de Sanofi s’enrichit de nouvelles données sur l’asthme et prévoit de nouvelles études cliniques sur la BPCO

Communiqué de presse : Le portefeuille de traitements contre les maladies respiratoires de Sanofi s’enrichit de nouvelles données sur l’asthme et prévoit de nouvelles études cliniques sur la BPCO

Le portefeuille de traitements contre les maladies respiratoires de Sanofi s’enrichit de nouvelles données sur l’asthme et prévoit de nouvelles études cliniques sur la BPCO De nouvelles données de phase II démontrent l’efficacité de l’amlitélimab dans le …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service